Semaglutide mimics GLP-1 (glucagon-like-peptide-1) to reduce hunger and cravings. This allows for easy reduction of food intake, resulting in weight loss with no diet struggles, lifestyle changes or intense exercise routines. 

MO combines the medication with treatments using proven MedSpa technology of eMuscle Tone and RedLight Body to tone muscle and tighten skin.

Semaglutide also regulates blood sugar levels, improves blood pressure and cholesterol levels and improves quality of life through increased energy and improved mobility.

During your complimentary consultation, the Medical Director will determine if the weekly Semaglutide + B12 weight loss medication is right for you, review the WeightLoss by MO program and complete your lab work.

For the next four weekly visits at MO MedSpa, you’ll receive the weight loss injection and learn how to self-administer it. Throughout your program, we will monitor your weight loss program and track your progress through lab work and 3D imaging. Depending on your WeightLoss program, you will also receive body treatments to tone muscle and tighten your skin.

After the 4th week, you may self-administer the Semaglutide medication at home.

Semaglutide is safe and effective across a wide spectrum of people: men and women, older and younger, and of any race/ethnicity. Individuals may benefit from semaglutide even if they previously struggled with weight loss through changes in lifestyle, diet and exercise.

The Medical Director provides a free evaluation to each candidate to ensure safety and success.

Everything you need for weight loss success.

• Semaglutide+B12 Medication
• Tone and Tighten Treatments
• Medical Monitoring including:
  • Lab work 
  • 3D Body Scans
    

In the trial “Once-Weekly Semaglutide in Adults with Overweight or Obesity” published in The New England Journal of Medicine the following are side effects reported by some participants.

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Headache
• Abdominal Pain

Review trial here

Briefing Contributors. (2023, March 2). A new class of drugs for weight loss could end obesity. The Economist. A new class of drugs for weight loss could end obesity

 Cummings, D. E., Weigle, D. S., Frayo, R. S., Breen, P. A., Ma, M. K., Dellinger, E. P., & Purnell, J. Q. (2002). Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. New England Journal of Medicine, 346(21), 1623–1630. https://doi.org/10.1056/nejmoa012908

Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): A randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial – ScienceDirect

 Drucker, D. J. (2018). Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism, 27(4), 740–756. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1 – ScienceDirect

 Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., … & Brown, K. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515.https://www.nejm.org/doi/10.1056/NEJMoa2107519.

Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., & Wharton, S. (2022). Two-year effects of semaglutide in adults with overweight or obesity: The step 5 trial. Nature Medicine, 28(10), 2083–2091. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial | Nature Medicine

 Ghusn, W., De la Rosa, A., Sacoto, D., Cifuentes, L., Campos, A., Feris, F., Hurtado, M. D., & Acosta, A. (2022). Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity. JAMA network open, 5(9), e2231982. https://doi.org/10.1001/jamanetworkopen.2022.31982

Howland, J. (2023, May 24). Mayo Clinic Minute: What’s the skinny on weight-loss drugs? Mayo Clinic. Mayo Clinic Minute: What’s the skinny on weight-loss drugs?

Kushner, R. F., Calanna, S., Davies, M., Dicker, D., Garvey, W. T., Goldman, B., … & Rubino, D. (2020). Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity, 28(6), 1050-1061.

  Le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DC, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomized, double blind trial. The Lancet. 2017 Apr 8;389(10077):1399-409. https://doi.org/10.1016/S0140-6736(17)30069-7.

Loftus, P. (2022, June 21). A promising weight-loss aid emerges: Diabetes drugs. The Wall Street Journal. https://www.wsj.com/articles/a-promising-weight-loss-aid-emerges-diabetes-drugs-11655823679?mod=Searchresults_pos14&page=1

 Loftus, P. (2023, May 22). Ozempic: How the diabetes drug works and why it’s such a big deal for weight loss. The Wall Street Journal. https://www.wsj.com/articles/ozempic-diabetes-drug-weight-loss-c0e03c25?mod=Searchresults_pos3&page=1

 Mayo Clinic Staff. (2022, October 29). Pros and cons of weight-loss drugs. Mayo Clinic. Prescription weight-loss drugs: Can they help you? – Mayo Clinic

 Office of the Commissioner. (2021, June 4). FDA approves new drug treatment for Chronic Weight Management, first since 2014. U.S. Food and Drug Administration. FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014

O’Brien, S. A. (2022, October 12). How a diabetes drug became the talk of Hollywood, Tech and the Hamptons. The Wall Street Journal. https://www.wsj.com/articles/ozempic-weight-loss-diabetes-drug-11665520937?mod=Searchresults_pos11&page=1

 O’Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: A randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 392(10148), 637–649. https://doi.org/10.1016/s0140-6736(18)31773-2

 Rimler, R., Zukerman, W., Natowicz, R. E., Horn, M., Werner, J., & Dang, M. (n.d.). Weight Loss Meds: Is Ozempic a Miracle Drug? Science Vs. episode. Retrieved June 8, 2023, from https://open.spotify.com/episode/2RpoJhkHbUNHk6WNtoJLyv.

 Wadden, T. A., Bailey, T. S., Billings, L. K., Davies, M., Frias, J. P., Koroleva, A., Lingvay, I., O’Neil, P. M., Rubino, D. M., Skovgaard, D., Wallenstein, S. O., & Garvey, W. T. (2021). Effect of subcutaneous semaglutide vs Placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA, 325(14), 1403. https://doi.org/10.1001/jama.2021.1831

Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/nejmoa2032183 

Members Only MedSpa is so confident in WeightLoss by MO that they guarantee your waist size will be smaller by the end of your 6-month program or your money back. To be eligible for a 100% refund, you must fully commit to the simple and effective weight loss program. This includes:

• Taking your weekly prescribed dose of weight loss medication as directed
• Receiving at least 3, 1-hour MedSpa treatments per month
• Responding to all monthly follow-up surveys
• Coming into MO MedSpa for all blood draws and follow-up appointments
• Being up to date with any outstanding balances on your account

If you follow these steps and your waist measurement isn’t any smaller than when you started, we will refund 100% of your program cost.